NanoRepro AG (NN6) Fair Value & Analysis
Healthcare · DE · Market cap €23.1M
Fair value as of: Jun 25, 2026
Analysis
NanoRepro AG (NN6) currently trades at €2.09, while our model-based Fair Value estimate is €1.83 — implying the stock looks roughly 12.4% overvalued today. We read business quality at 92/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
About the company
NanoRepro AG engages in the development, manufacture, and distribution of rapid diagnostic tests and food supplements for home and professional use in Germany and internationally. The company provides products in the areas of family planning and disease detection, as well as food intolerances, allergies, and infectious diseases. It offers rapid diagnostic tests, such as family planning, and preventive healthcare line products. The company also develops and commercializes immunochromatographic lateral flow tests; and tests for hospitals and medical practices. The company is headquartered in Marburg, Germany.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is NanoRepro AG (NN6) undervalued?
What is the fair value of NN6?
What is the quality score of NN6?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.